0000899243-18-017963.txt : 20180625
0000899243-18-017963.hdr.sgml : 20180625
20180625181527
ACCESSION NUMBER: 0000899243-18-017963
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180625
FILED AS OF DATE: 20180625
DATE AS OF CHANGE: 20180625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Booth Bruce
CENTRAL INDEX KEY: 0001451612
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38537
FILM NUMBER: 18917901
MAIL ADDRESS:
STREET 1: 890 WINTER STREET
STREET 2: SUITE 320
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVROBIO, Inc.
CENTRAL INDEX KEY: 0001681087
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 810710585
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BLDG. 300, SUITE 201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7819626030
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BLDG. 300, SUITE 201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AvroBio, Inc.
DATE OF NAME CHANGE: 20160729
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-25
0
0001681087
AVROBIO, Inc.
AVRO
0001451612
Booth Bruce
C/O AVROBIO, INC.
1 KENDALL SQUARE, BUILDING 300, STE 201
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2018-06-25
4
C
0
806711
A
806711
I
See Footnote
Common Stock
2018-06-25
4
C
0
3044579
A
3851290
I
See Footnote
Common Stock
2018-06-25
4
C
0
905188
A
4756478
I
See Footnote
Series Seed Preferred Stock
2018-06-25
4
C
0
3333333
0.00
D
Common Stock
806711
0
I
See footnote
Series A Preferred Stock
2018-06-25
4
C
0
12580199
0.00
D
Common Stock
3044579
0
I
See footnote
Series B Preferred Stock
2018-06-25
4
C
0
3740239
0.00
D
Common Stock
905188
0
I
See footnote
Represents the total number of shares of Common Stock received by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"), upon the conversion of the Issuer's Series Seed Preferred Stock in connection with the closing of the Issuer's initial public offering.
The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.
/s/ Bruce Booth
2018-06-25